Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 14, 2026Cardiovascular UltrasoundOpen Access

Advanced imaging, genetic testing, and cardiac myosin inhibitors improve HCM diagnosis, risk stratification, and management.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Advances in cardiovascular imaging, genetic testing, and targeted therapies have significantly evolved the diagnosis, risk stratification, and management of hypertrophic cardiomyopathy.

Design

Review

Key result

Advances in cardiovascular imaging, genetic testing, and targeted therapies such as cardiac myosin inhibitors have significantly improved the diagnosis, risk stratification, and management of hypertrophic cardiomyopathy.

Authors

EFEluisa La FrancaFPFrancesca ParisiALAlessandro Lucchino

Discussion

Loading...

Member takes

Overview

May refine HCM pathways with multimodal tools; leaves open comparative trials and equitable access.

Key Points

  • To review the evolving diagnostic landscape, risk assessment strategies, and contemporary pharmacological and interventional management of hypertrophic cardiomyopathy.
  • Synthesized evidence on noninvasive imaging modalities, including transthoracic echocardiography and cardiac magnetic resonance imaging, alongside genetic testing workflows.
  • Evaluated conventional first-line pharmacotherapies, invasive septal reduction techniques, and newly developed targeted molecular inhibitors.
  • Echocardiography remains the primary imaging modality for baseline evaluation, while cardiac magnetic resonance imaging provides critical supplementary data regarding myocardial fibrosis quantification and anatomical measurements.
  • First-line medical therapy centers on negative inotropic agents such as beta-blockers, calcium channel blockers, and disopyramide, with septal reduction reserved for drug-refractory obstructive cases.
  • Targeted cardiac myosin inhibitors have emerged as effective disease-specific agents that significantly decrease left ventricular outflow tract gradients and relieve clinical symptoms.

Structured PICO

P
Population
Individuals with hypertrophic cardiomyopathy
I
Intervention
Diagnostic and management strategies including echocardiography, cardiac magnetic resonance imaging, genetic testing, pharmacological therapy, and septal reduction techniques

This review provides a comprehensive overview of established and emerging diagnostic and therapeutic strategies for hypertrophic cardiomyopathy.

Cite This Study

Franca et al. (2026) conducted a review in Hypertrophic cardiomyopathy. Diagnosis and management strategies was evaluated. Advances in cardiovascular imaging, genetic testing, and targeted therapies such as cardiac myosin inhibitors have significantly improved the diagnosis, risk stratification, and management of hypertrophic cardiomyopathy.

synapsesocial.com/papers/6aa7b0c179e9260bc85aad4bhttps://doi.org/10.1186/s12947-026-00382-6
View Full Paper
Ask AI
Bookmark
Share